Business Wire

HANSHOW

30.5.2022 09:02:12 CEST | Business Wire | Press release

Share
Hanshow Releases Its New IoT Platform, Elevating Retail Digitalization

European retailers are some of the world’s earliest adopters of electronic shelf labels (ESLs) to reduce operations costs as a foundation for retail digitalization. Now at this week’s EuroCIS 2022 trade show, the new IoT platform All-Star is being released and introduced by the digital solutions provider Hanshow (EuroCIS booth - 9 D13), poised to drive Europe’s brick‐and‐mortar retail into a new era of efficiency and profitability.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005588/en/

Entering the European market in 2016, Hanshow has been a major driver of this transformation with now nearly 100 million ESLs installed on the continent. This time at EuroCIS 2022, Hanshow is displaying a range of new solutions from AI-powered shelf monitoring to self-checkout trolleys and in-store marketing, constantly shaping smart stores of the future.

Chief among the new technologies presented by Hanshow at EuroCIS is the IoT platform All-Star, focusing on the retail industry and designed specifically to help retailers to expand and upgrade their digitalization. All-Star provides one-stop IoT solutions from IoT device management to digital operations upgrades, empowering retail customers to quickly establish IoT equipment management capabilities and be able to flexibly build business applications and integrate customized business connections to further boost operation efficiency of smart stores and elevate in-store experience of the customers, ranging over key functions of pricing management, inventory management, picking, geolocation, dynamic pricing, promotion boards, interactive marketing, digital payment, passenger flow analysis and automatic monitoring patrol.

The All‐Star platform thus works as an integrated system for the management of a store’s entire digital devices, providing SaaS and private deployment solutions, both of which support unified user authentication and third-party application access integration with an open API based on HTTP. Correspondingly, one of its key product innovations is to solve the new challenges arising with the amount of IoT devices all operating on different networks and communicating on different transmission signals, as one store may require a handful of login systems with operations personnel trained in each. Therefore, each retail solution management platform may now be accessed through All-Star for a holistic integration of all the core business operation processes, significantly simplifying the maintenance of these devices.

In tandem with the All-Star system, Hanshow has also developed an industry-first communications protocol that uses one transmission frequency to communicate with all Hanshow IoT devices, easing the burden on the range of signal frequencies previously needed.

“Hanshow has developed All-Star and the rest of its solutions specifically with global retailers in mind to achieve a more holistic form of digitalization. These new solutions, software, and transmission technologies all combine to help retailers in Europe move into an exciting new era of digitalization,” said Shiguo Hou. “This unlocks great new opportunities. We’re just seeing the beginning of what’s possible.”

About Hanshow

Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. Hanshow is dedicated to offering its global customers a series of world‐class customized IoT touchpoints and digital store solutions that deliver customer‐centric insights, helping retailers streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Hanshow currently serves over 30,000 stores in more than 50 countries. Learn more: www.hanshow.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye